LE WE PMID CA
HDAC611147HDAC6

ACY1215 ttHDAC6

Aggresome

Bortezomib ttProteasom

DAPK1

ERS UFR (Apoptosis)

Flt3ITD

HDAC2

Leukemia (acute myeloic)

NFKB

Suberoylanilide hydroxamic acid ttHDAC6

TAK1

2012  
1
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
[22262760] Blood 119(11): 2579-89 (2012)
2006  
2
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
[16585204] Cancer Res 66(7): 3773-81 (2006)
2012  
3
A noncanonical Flt3ITD/NF-kappaB signaling pathway represses DAPK1 in acute myeloid leukemia.
[22096027] Clin Cancer Res 18(2): 360-9 (2012)
2008  
4
The aggresome pathway as a target for therapy in hematologic malignancies.
[18472289] Mol Genet Metab 94(3): 283-6 (2008)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • HDAC6

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia